Arcturus Therapeutics Holdings

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARCT and other ETFs, options, and stocks.

About ARCT

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF.

CEO

Joseph E. Payne

CEOJoseph E. Payne

Employees

176

Employees176

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

2013

Founded2013

Employees

176

Employees176

ARCT Key Statistics

Market cap

315.52M

Market cap315.52M

Price-Earnings ratio

-4.61

Price-Earnings ratio-4.61

Dividend yield

—

Dividend yield—

Average volume

468.88K

Average volume468.88K

High today

$11.84

High today$11.84

Low today

$10.55

Low today$10.55

Open price

$10.80

Open price$10.80

Volume

381.31K

Volume381.31K

52 Week high

$45.00

52 Week high$45.00

52 Week low

$8.04

52 Week low$8.04

ARCT News

Simply Wall St 2d

Arcturus Therapeutics Holdings First Quarter 2025 Earnings: Beats Expectations

Arcturus Therapeutics Holdings ( ) First Quarter 2025 Results Key Financial Results Revenue: US$29.4m (down 23% from 1Q 2024). Net loss: US$14.1m (loss narro...

TipRanks 3d

Arcturus Therapeutics reports Q1 EPS (52c), consensus ($1.10)

Reports Q1 revenue $29.38M, consensus $23.35M. “We are delighted with enrollment in our cystic fibrosis (CF) program, and the company is working diligently to p...

Analyst ratings

100%

of 11 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own ARCT. This list is generated using Robinhood data, and it’s not a recommendation.